A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy–induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial

Eitemau Tebyg

• Antiretroviral Therapy–Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial
  gan: Ofotokun, Ighovwerha, et al.
  Cyhoeddwyd: (2019)
• T cell RANKL/OPG imbalance is associated with HIV-induced bone loss in patients with higher CD4(+) T cell counts
  gan: TITANJI, Kehmia, et al.
  Cyhoeddwyd: (2018)
• Dysregulated B Cell Expression of RANKL and OPG Correlates with Loss of Bone Mineral Density in HIV Infection
  gan: Titanji, Kehmia, et al.
  Cyhoeddwyd: (2014)
• Antiretroviral Therapy Induces a Rapid Increase in Bone Resorption that is Positively Associated with the Magnitude of Immune Reconstitution in HIV Infection
  gan: Ofotokun, Ighovwerha, et al.
  Cyhoeddwyd: (2016)
• Immature/transitional B cell expansion is associated with bone loss in HIV-infected individuals with severe CD4(+) T cell lymphopenia
  gan: TITANJI, Kehmia, et al.
  Cyhoeddwyd: (2020)